Healthcare Review: Community Health Systems, Dehaier Medical, BioLineRX, Oncolytics Biotech, Isis Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Monday, 09 September 2013 12:51
U.S. stocks and bonds rallied on Monday while the dollar fell against most major currencies as upbeat economic data from China allowed the S&P 500 to advance for the fifth straight day and concern about the possibility of a Western strike against Syria fed a bid for safe-haven U.S. debt.  Following Friday's soft U.S. jobs report, debate persisted over when, and by how much, the U.S. Federal Reserve would begin to reduce its stimulative bond-buying program. Most economists think the Fed will announce a cut in bond purchases next week, a Reuters poll showed on Monday.

Community Health Systems (CYH -3.9%) slips after Citigroup cut the shares from Buy to Neutral earlier, and lowered its price target from $60 to $42.The firm says that while CYH's potential deal with HMA represents an accretive acquisition of complimentary assets, it also increases its financial leverage, operating and legal risk.Citi is concerned that Q3 results for both companies could lead to another round of estimate reductions.

Shares of Dehaier Medical Systems (DHRM +2.7%) tick higher after announcing it's landed a procurement agreement worth about $600K to supply the Beijing Kanglian Medicine Company.The company will supply Color Doppler Ultrasound machines and monitors to county hospitals and clinics in rural areas of China.

BioLineRX (BLRX +13.4%) soars after BL-8040 gets an Orphan Drug Designation for acute myeloid leukemia.Partial results from a Phase 2 study are due later this year.CEO Kinneret Savitsky says the treatment can be "a significant addition to the drug arsenal for [AML], especially when considering its promising preclinical results, unique biological mechanism and ability to synergize with other [approved] drugs."

Oncolytics Biotech (ONCY) announces tumor response data from a Phase 2 trial of its human reovirus variant Reolysin in patients with squamous cell carcinoma of the lung.Out of 25 patients who got more than one cycle of therapy, 23 exhibited overall tumor shrinkage.CEO Brad Thompson is "thrilled."Mean tumor shrinkage was 32.7%.

Isis Pharmaceuticals (ISIS) jumps 9.2% premarket after announcing a strategic collaboration with Biogen (BIIB) to develop treatments for neurological disorders using ISIS' antisense technology.The terms of the six-year deal given BIIB exclusive rights to ISIS' technology and call for an upfront payment to ISIS of $100M.ISIS is eligible to receive up to $220M in milestone payments on antisense molecules and may also receive additional funds to cover the costs of clinical trials.The upfront payment will be charged to R&D expense for BIIB in Q3.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter